Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Zuclomiphene · Veru-944, RMI-16312

Small molecule · Agonist of estrogen receptor (ESR1) · developed by Repros Therapeutics

Phase 2 Most advanced trial (none active)
1 Registered trials

What is Zuclomiphene?

Zuclomiphene is the cis isomer of clomiphene, a weak estrogen receptor agonist. It is evaluated for treatment of hot flashes in men with advanced prostate cancer on androgen deprivation therapy and has been studied for antineoplastic activity in breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Veru-944, RMI-16312
Drug type
Small molecule
Targets
estrogen receptor (ESR1)
Mechanism
Agonist of estrogen receptor (ESR1)
Therapy area
Oncology
Developer
Repros Therapeutics Inc.
In trials of
VERU
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
3JU1DU3652

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03646162 Phase 2 Prostate Cancer Metastatic Completed VERU

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Prostate Cancer Metastatic

Other drugs acting on ESR1

Camizestrant FDA approved Ethinyl Estradiol/Levonorgestrel FDA approved Imlunestrant FDA approved Segesterone Acetate and Ethinyl Estradiol FDA approved Tamoxifen FDA approved Vepdegestrant FDA approved Giredestrant Phase 1/2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.